Retatrutide vs Liraglutide

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

Retatrutide: BLiraglutide: A

Attribute	Retatrutide	Liraglutide
Category	Metabolic / Triple Agonist	Metabolic / GLP-1 Agonist
Evidence Rating	B — Phase III / NDA Filed	A — FDA Approved
Clinical Status	Phase 3 clinical trials (Eli Lilly TRIUMPH program)	FDA-approved (Victoza for T2D, Saxenda for obesity)
Mechanism	Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal...	Liraglutide binds to GLP-1 receptors on pancreatic β-cells, increasing intracellular cAMP and triggering glucose-dependent insulin secretion. It suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake and increase satiety. A fatty acid (C1...
Half-Life	~6 days (allows once-weekly dosing)	~13 hours
Bioavailability	SC injection	~55% SC
Molecular Weight	—	~3,751 g/mol
WADA Status	Not Prohibited	Not Prohibited
Dosing	Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3, Once weekly (Subcutaneous (clinical trial formulation only))	Saxenda: 0.6-3.0 mg/day; Victoza: 0.6-1.8 mg/day, Once daily (Subcutaneous)
Key Use Cases	Weight Management Metabolic Health	Weight Management Metabolic Health Cardiovascular
Safety Concerns	GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter	Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%) GI side effects are dose-dependent and typically diminish over weeks FDA black box warning for thyroid C-cell tumors (rodent data)
Contraindications	Not yet established -- product is investigational Likely similar to GLP-1 class: personal/family history of medullary thyroid carcinoma, MEN2 (precautionary) Pregnancy (based on GLP-1 class) Monitoring recommended for muscle mass, bone density, GI motility per GLP-1 class concerns	Personal or family history of medullary thyroid carcinoma Multiple endocrine neoplasia syndrome type 2 (MEN2) History of pancreatitis Pregnancy (category X for Saxenda)
Regulatory (US)	Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028.	FDA-approved: Victoza (T2D, 2010), Saxenda (obesity, 2014). Prescription only.

Shop Retatrutide

View Retatrutide Product

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All Comparisons Browse Catalog

Retatrutide vs Liraglutide

Explore MoreComparisons

Your Cart

Explore More
Comparisons